Abstract Reaction of the precursor cis,fac-[RuCl2(dmso-S)3(dmso-O)] with three carbazate ligands led to new compounds of the type cis,fac-[RuCl2(dmso-S)3(L)] (L = benzylcarbazate (bc), 1; 4-methoxybenzylcarbazate (mc), 2; or 3,5-dimethoxy-α,α-dimethylbenzylcarbazate (mmc), 3). Complexes 1–3 have been characterized by elemental analysis (CHN), FTIR, UV–vis, and 1H and 13C{1H} NMR spectroscopy. Complex 1 was also analyzed by single-crystal X-ray diffraction and theoretical calculations were performed in order to better understand its spectroscopic data and electronic structure. All collected data were consistent with substitution of one dmso ligand by a monodentate carbazate ligand. Preliminary biological assays against breast and prostate human cancer cell lines were performed in order to evaluate the cytotoxic activity of these three new complexes. Graphical Abstract

中文翻译：

---

Ru(II)/DMSO 配合物与单配位碳酸盐配体的合成、光谱表征和计算研究

摘要 前体 cis,fac-[RuCl2(dmso-S)3(dmso-O)] 与三个氨基甲酸酯配体的反应产生了 cis,fac-[RuCl2(dmso-S)3(L)] 类型的新化合物(L = 苄基氨基甲酸酯 (bc)，1；4-甲氧基苄基氨基甲酸酯 (mc)，2；或 3,5-二甲氧基-α,α-二甲基苄基氨基甲酸酯 (mmc)，3）。配合物 1-3 已通过元素分析 (CHN)、FTIR、UV-vis 以及 1H 和 13C{1H} NMR 光谱进行表征。为了更好地理解其光谱数据和电子结构，还通过单晶 X 射线衍射分析了配合物 1 并进行了理论计算。所有收集的数据都与一个 dmso 配体被单齿氨基甲酸酯配体取代一致。进行了针对乳腺癌和前列腺人癌细胞系的初步生物学分析，以评估这三种新复合物的细胞毒活性。